US6951271005 - Common Stock
PACIRA BIOSCIENCES INC
NASDAQ:PCRX (7/1/2024, 12:47:50 PM)
28.76
+0.15 (+0.52%)
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 713 full-time employees. The company went IPO on 2011-02-03. The firm is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The firm is developing interventions to address debilitating conditions involving the sympathetic nervous system. The firm's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
PACIRA BIOSCIENCES INC
5401 West Kennedy Boulevard, Suite 890
Tampa FLORIDA 07054
P: 18135536680
CEO: David Stack
Employees: 713
Website: https://www.pacira.com/
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals.
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside...
Here you can normally see the latest stock twits on PCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: